Back to top
more

Catalyst Pharmaceuticals, Inc. (CPRX)

(Delayed Data from NSDQ)

$4.83 USD

4.83
1,450,987

+0.16 (3.43%)

Updated May 7, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (205 out of 254)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Earnings Preview: Catalyst Pharmaceutical (CPRX) Q1 Earnings Expected to Decline

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Catalyst (CPRX) Up 8.9% Since Last Earnings Report?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst (CPRX) Beats on Q4 Earnings, Revenues Rise Y/Y

Catalyst's (CPRX) earnings and revenues beat estimates in the fourth quarter of 2020.

Catalyst Pharmaceutical (CPRX) Beats Q4 Earnings and Revenue Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and 3.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Spectrum's (SPPI) NSCLC Drug Gets FDA's Fast Track Designation

The FDA grants a Fast Track designation to Spectrum Pharmaceuticals' (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations.

Cassava Sciences (SAVA) Up More Than 600% YTD: Here's Why

Cassava Sciences (SAVA) is progressing well with development of its Alzheimer's disease candidate, simufilam.

Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catayst (CPRX) Provides Long-Term Portfolio Expansion Plans

Catalyst (CPRX) plans to expand its product portfolio beyond Firdapse.

Catalyst Pharmaceuticals (CPRX) Jumps: Stock Rises 5.5%

Catalyst Pharmaceuticals (CPRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Why Is Catalyst (CPRX) Up 4.4% Since Last Earnings Report?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst's (CPRX) Q3 Earnings Beat Estimates, Revenues Miss

Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2020.

Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and -6.10%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?

Catalyst (CPRX) will provide updates on earnings and revenues when its releases third-quarter 2020 results.

Why Is Catalyst (CPRX) Down 7.5% Since Last Earnings Report?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst (CPRX) Eyes Firdapse Label Expansion Amid Competition

Catalyst's (CPRX) efforts to expand Firdapse label are encouraging. However, with only a few candidates in the pipeline, the company's dependence on Firdapse for growth remains a matter of concern.

Catalyst's (CPRX) Q2 Earnings & Revenues Beat Estimates

Catalyst (CPRX) beats both earnings and sales estimates in the second quarter of 2020.

Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 12.50% and 2.20%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Catalyst Pharmaceutical (CPRX) Q2 Earnings Expected to Decline

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalyst (CPRX) Down 0.4% Since Last Earnings Report: Can It Rebound?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss

Catalyst (CPRX) beats on Q1 earnings but misses on revenues. It also withdraws sales guidance due to the coronavirus pandemic.

Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 11.11% and -8.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Catalyst (CPRX) Up 52.1% Since Last Earnings Report: Can It Continue?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst's (CPRX) Q4 Earnings Miss Estimates, Revenues Meet

Catalyst's (CPRX) earnings lag estimates in the fourth quarter. Revenues match the same.

Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About Catalyst (CPRX) Stock We Don't?

Investors need to pay close attention to Catalyst (CPRX) stock based on the movements in the options market lately.